Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pediatr Neurol. 2006 Sep;35(3):220-2.

Maternal lamotrigine treatment and elevated neonatal gamma-glutamyl transpeptidase.

Author information

  • 1Department of Neonatology, Rabin Medical Center, Beilinson Campus, Schneider Children's Medical Center of Israel, Petah Tiqva, Israel. gal-d@bezeqint.ne

Abstract

Lamotrigine is an antiepileptic drug with a low adverse-effect profile. This report describes an infant born to an epileptic mother treated with lamotrigine, who had a highly elevated gamma-glutamyl transpeptidase level after birth. There was no other clinical or biochemical evidence of liver or bile duct dysfunction. Infant serum level of lamotrigine, which crosses the placenta, was within therapeutic limits. Gamma-glutamyl transpeptidase levels declined slowly during the following months. We suggest that, in the absence of additional markers of tissue damage, the infant's gamma-glutamyl transpeptidase elevation was caused by maternal intake of lamotrigine. Liver function tests should be monitored in infants of lamotrigine treated mothers, as enzyme elevation might still suggest liver damage.

PMID:
16939865
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk